MedTrace Logo

A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

NCT07462143 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-05-22

No results posted yet for this study

Summary

This is a Phase Ⅱ/Ⅲ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)

Conditions

  • Colorectal (Colon or Rectal) Cancer

Interventions

DRUG

RC148 (Dose 1) plus Capecitabine and Oxaliplatin

RC148 (Dose 1) plus Capecitabine and Oxaliplatin

DRUG

RC148 (Dose 2) plus Capecitabine and Oxaliplatin

RC148 (Dose 2) plus Capecitabine and Oxaliplatin

Sponsors & Collaborators

  • RemeGen Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-12
Primary Completion
2027-05-12
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07462143 on ClinicalTrials.gov